Alemtuzumab

Timothy A. Weaver, Allan D. Kirk*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

33 Scopus citations

Abstract

Alemtuzumab is a humanized CD52-specific monoclonal antibody that is increasingly used off-label as an induction agent in solid organ transplantation, particularly in the setting of maintenance immunosuppression minimization protocols. In this review, we briefly discuss this agent's mechanisms of action and summarize evidence supporting its use in this clinical setting.

Original languageEnglish
Pages (from-to)1545-1547
Number of pages3
JournalTransplantation
Volume84
Issue number12
DOIs
StatePublished - Dec 2007
Externally publishedYes

Keywords

  • Alemtuzumab
  • Immunosuppression
  • Lymphocyte depletion
  • Monoclonal antibody

Fingerprint

Dive into the research topics of 'Alemtuzumab'. Together they form a unique fingerprint.

Cite this